Amgen posts Phase 2 data for immunotherapy in lung cancer
Amgen (NASDAQ:AMGN) introduced Friday that its Section 2 DeLLphi-301 research for bispecific T-cell engager tarlatamab confirmed an goal response charge ...
Tag: Amgen
Amgen (NASDAQ:AMGN) introduced Friday that its Section 2 DeLLphi-301 research for bispecific T-cell engager tarlatamab confirmed an goal response charge ...